Plus   Neg

AstraZeneca: Farxiga Meets Primary Endpoint In Phase III Trial - Quick Facts

AstraZeneca plc (AZN.L,AZN) reported positive results from the Phase III DAPA-HF trial, the first heart failure outcomes trial with an SGLT2 inhibitor in patients with and without type-2 diabetes. In the trial, Farxiga showed efficacy and safety data for the treatment of patients with heart failure on top of standard of care. The safety profile was consistent with the established safety profile of the medicine.

AstraZeneca said it plans to discuss the results of the DAPA-HF trial with health authorities as soon as possible.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Lowe's Companies Inc. (LOW) and Office Depot Inc. (ODP) reported profit for their fourth-quarter, while TJX Companies' (TJX) profit increased 17 percent from the prior year. TJX plans to increase dividend by 13 percent and to buy back up to $2.25 billion of stock. Starbucks is introducing plant-based meat to its menu in Canada in early March. The Seattle-based coffee chain said it will introduce a new Beyond Meat, Cheddar and Egg Sandwich to its Canadian stores on March 3, along with the launch of its new spring menu. The meatless breakfast sandwich will be part of Starbucks Canada's core menu. Auto major Ford Motor Co. issued a safety compliance recall for a total of 217,185 F-150 pickup trucks with LED headlamps in North America, including 50,989 in Canada, to fix issues with the headlamps that could increase risk of a crash. The F-150 has been the top selling U.S. vehicle by any manufacturer for more than 40 years.
Follow RTT